Discover: Safeguarding Critical Capability During M&A Through Talent Cross‑Pollination at Blueprint Medicines
- How can mid‑sized life sciences organizations sustain engagement and operational stability during a prolonged acquisition and six‑month talent‑at‑risk period?
- Learn how Blueprint Medicines implemented a practical talent cross‑pollination and contingency planning approach, redeploying internal capability, redistributing work, and partnering closely with HRBPs to reduce reliance on external hiring
- Discover how this strategy protected critical roles, supported meaningful stay conversations, and enabled employees to remain engaged and productive through uncertainty, offering a repeatable model for organizations navigating M&A or commercial scale‑up